Articles · HRT

Non-Hormonal Hot Flash Treatments

From fezolinetant to SNRIs and gabapentin: what the evidence actually shows.

6 min read · Published May 30, 2026 · Updated August 28, 2026

Sourced from peer-reviewed research and clinical guidelines, cited at the end of this article. How we write about your body.

Non-Hormonal Hot Flash Treatments

For women who cannot or would rather not use hormone replacement therapy, managing hot flashes has long meant limited options. That changed in May 2023, when the FDA approved fezolinetant (Veozah), the first drug of a new class to target hot flashes directly without hormones.

This article covers the main non-hormonal prescription options, what each one does, what the trial evidence shows, and what to weigh when discussing them with your doctor.

Who Needs Non-Hormonal Treatment

The women most likely to need non-hormonal treatment fall into a few groups: those with a personal history of hormone-receptor-positive breast cancer (for whom systemic estrogen is generally not advised), those taking tamoxifen or aromatase inhibitors for breast cancer treatment, those with a history of blood clots, and those who prefer not to use hormonal therapy.

Hot flashes in women undergoing breast cancer treatment are often severe, partly because tamoxifen and aromatase inhibitors directly reduce estrogen activity. This group has driven much of the trial evidence for non-hormonal options.

Fezolinetant (Veozah): A New Mechanism

Fezolinetant works on a different pathway than any previous hot flash treatment. The mechanism centres on KNDy neurons in the hypothalamus, the temperature-control region of the brain.

During the transition, falling estrogen increases neurokinin B (NKB) signalling at KNDy neurons. This overactivation destabilises the body’s temperature set point and directly drives hot flashes. Fezolinetant is a selective neurokinin-3 receptor blocker: it stops NKB from binding to its receptor on KNDy neurons, calming the overactivation and reducing hot flash frequency.[1]

SKYLIGHT trial results. In the pivotal phase 3 trials, fezolinetant 30 mg reduced hot flash frequency from 10.7 events per 24 hours at baseline to 4.5 events at week 12, a 56% average reduction. The 45 mg dose reduced frequency from 10.4 to 4.1 events per 24 hours, a 61% reduction. These improvements held through 52 weeks.[2]

The liver injury warning. The FDA has added a boxed warning for a rare risk of serious liver injury. Liver function tests are required before starting, after three months, and after six months. The drug should be stopped if signs of liver injury appear: jaundice, dark urine, unusual fatigue, right upper abdominal pain. Women with existing liver disease should not use it. Discuss this with a prescriber before starting.[3]

Fezolinetant is approved for moderate to severe hot flashes and is a real advance for women who need a non-hormonal option, especially those in cancer treatment. The liver monitoring requirement is a real constraint on access.

Paroxetine (Brisdelle): FDA-Approved Since 2013

Low-dose paroxetine CR (7.5 mg), sold as Brisdelle, was the first non-hormonal drug specifically approved by the FDA for hot flashes. It is an SSRI at a dose lower than the one used for depression.

The mechanism is not fully understood, but SSRIs appear to reduce the central nervous system activity that contributes to temperature instability. In trials, paroxetine at this dose reduced hot flash frequency by roughly 37 to 47%, versus 13 to 24% for placebo.[4]

For breast cancer patients. Paroxetine is a strong CYP2D6 inhibitor and reduces the effectiveness of tamoxifen by blocking its conversion to the active form, endoxifen. It should not be used alongside tamoxifen, which rules it out for a large share of the women who most need non-hormonal options.

Other SSRIs and SNRIs

Several antidepressants have evidence for reducing hot flash frequency, even though they are not approved for it.

Venlafaxine and desvenlafaxine (SNRIs) have the strongest antidepressant-class evidence for hot flashes. Venlafaxine at 75 mg/day reduces hot flash frequency by around 37 to 60% in trials.[5] Desvenlafaxine at 100 to 150 mg/day shows similar results. Both are useful for women who also have mood symptoms, since they treat both.

Escitalopram has trial evidence for hot flash reduction at 10 to 20 mg/day, with fewer drug interactions than paroxetine and better tolerability for many women.

Neither venlafaxine nor escitalopram interferes with tamoxifen metabolism to any meaningful degree, which makes them preferable to paroxetine for women on tamoxifen.

The effect is smaller than for estrogen. SSRIs and SNRIs work, but they are second-tier to hormonal treatment for women with no reason to avoid it.

Gabapentin

Gabapentin is an anticonvulsant that reduces hot flash frequency and severity through unclear mechanisms, possibly by steadying the body’s automatic response to temperature changes.

A review and meta-analysis found that gabapentin reduced hot flash frequency and composite scores by 45 to 71% from baseline across the included trials.[6] The effective dose for hot flashes is usually 900 mg/day, split as 300 mg three times daily or 600 mg at night.

Side effects are a real constraint: drowsiness, dizziness, and unsteadiness are common, especially in the first one to two weeks. These usually improve by week four, but the adjustment period deters many women. A higher dose at bedtime uses the sedative effect while concentrating relief during the most disruptive hours.

Gabapentin is most useful when the main problem is night sweats disrupting sleep.

Choosing Between Options

Women with hormone-receptor-positive breast cancer or on aromatase inhibitors. Fezolinetant has the most targeted evidence and mechanism. Venlafaxine or desvenlafaxine are alternatives. Avoid paroxetine and fluoxetine due to tamoxifen interactions.

Women with significant mood symptoms alongside. SNRIs treat both. Starting an SNRI first is practical when mood is as prominent as hot flashes.

Women whose main problem is night sweats disrupting sleep. Gabapentin at night, or fezolinetant if liver monitoring is feasible.

Women who prefer not to use hormones but have no specific reason to avoid them. All the options above are available. HRT is still more effective than any of these for moderate to severe hot flashes, but that comparison does not matter if HRT is off the table.

None of these options addresses bone density, genital and urinary changes, or heart risk, which systemic HRT can. They are hot flash treatments, not broader menopausal treatments.


References

[1] Kerber, C., Pinkerton, J. V. (2023). FDA approves Veozah (fezolinetant) for menopausal symptoms: a new nonhormonal option. Journal of the Academy of Consultation-Liaison Psychiatry. https://pmc.ncbi.nlm.nih.gov/articles/PMC12401328/

[2] Fraser, G. L., Bhartiya, D., Gompel, A., et al. (2023). Efficacy and safety of fezolinetant in moderate to severe vasomotor symptoms associated with menopause: a phase 3 RCT. Journal of Clinical Endocrinology & Metabolism. https://pmc.ncbi.nlm.nih.gov/articles/PMC10348473/

[3] FDA Drug Safety Communication. FDA adds warning about rare occurrence of serious liver injury with use of Veozah (fezolinetant) for hot flashes due to menopause. https://www.fda.gov/safety/medical-product-safety-information/fda-adds-warning-about-rare-occurrence-serious-liver-injury-use-veozah-fezolinetant-hot-flashes-due

[4] Simon, J. A., Portman, D. J., Kaunitz, A. M., et al. (2013). Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms: two randomized controlled trials. Menopause, 20(10), 1027-1035. https://doi.org/10.1097/GME.0b013e3182a66aa7

[5] Loprinzi, C. L., Sloan, J., Stearns, V., et al. (2009). Newer antidepressants and gabapentin for hot flashes: an individual patient pooled analysis. Journal of Clinical Oncology, 27(17), 2831-2837. https://doi.org/10.1200/JCO.2008.19.6253

[6] Guttuso, T., Kurlan, R., McDermott, M. P., Kieburtz, K. (2003). Gabapentin’s effects on hot flashes in postmenopausal women: a randomized controlled trial. Obstetrics and Gynecology, 101(2), 337-345. See also systematic review and meta-analysis: https://www.ncbi.nlm.nih.gov/books/NBK76754/

Teala surfaces health patterns to help you and your doctor make informed decisions. It does not diagnose conditions or replace medical advice. Always consult a qualified healthcare professional about your symptoms and treatment.